PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
 

Press Releases

 
GTCbio

Press Release


Receive press releases from GTCbio: By Email RSS Feeds:

Dr. Raymond Deshaies Speak at 3rd Ubiquitin Research and Drug Discovery Conference Feb 25-26, 2013 in Las Vegas, NV


3rd Ubiquitin Research and Drug Discovery Conference organized by GTCbio company.

Las Vegas, NV, January 10, 2013 --(PR.com)-- Dr. Deshaies will speak at the 3rd Ubiquitin Research and Drug Discovery Conference organized by GTC.

Dr. Deshaies is Professor and Executive Officer of Biology at the California Institute of Technology and an Investigator at the Howard Hughes Medical Institute. His career has focused on investigating the cellular machinery that mediates protein degradation by the Ubiquitin-Proteasome System (UPS), and how this machinery regulates cell division. Dr. Deshaies is a leading figure in the Ubiquitin field, has published over 100 papers and is an inventor on nine U.S. patents, many related to his work on the UPS. For information on his work, visit http://www.its.caltech.edu/~rjdlab/. Dr. Deshaies has received numerous awards and scholarships, including the Markey and Searle Scholar Awards and Burroughs-Wellcome and Beckman New Investigator Award; in 1999 he was selected as Young Investigator of the Year by the American Society for Cell Biology and in 2011 was elected to the American Academy of Arts and Sciences. In addition to being a co-founder of Cleave Biosciences, Dr. Deshaies was the academic co-founder of Proteolix, which was sold in October 2009 to Onyx in a deal valued at up to $851 million.

The 3rd Ubiquitin Research and Drug Discovery Conference will bring together a 50-50 mix of academic and industry experts from leading affiliations (such as Elan, Millenium, Genentech, Celgene, Novartis, Onyx, Amgen, Cal-Tech, Emory University, Harvard, University of Washington, UCLA, etc.) to cover many current and relevant aspects of the Ubiquitin Proteasome Sturcture, Ligases, Sumo and more.

This conference is also part of the 2nd Novel Cancer Therapeutic Summit, which consists of this track and two others:
4th Cancer Targets and Therapeutics
2nd Oncology Partnering and Deal Making

For more information, please visit www.gtcbio.com
Contact Information
GTCbio
David Stoops
626-256-6405
Contact
http://www.gtcbio.com
434 W. Foothill Blvd.
Monrovia, CA 91016
fax: (626) 256-6460

Click here to view the list of recent Press Releases from GTCbio
Promote Your Business